Skip to main content

Tecentriq Prices, Coupons, Copay Cards & Patient Assistance

Tecentriq (atezolizumab) is a member of the anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) drug class and is commonly used for Alveolar Soft Part Sarcoma, Hepatocellular Carcinoma, Melanoma, and others.

The cost for Tecentriq (840 mg/14 mL) intravenous solution is around $8,232 for a supply of 14 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.

Tecentriq prices

Intravenous Solution

840 mg/14 mL

Tecentriq intravenous solution

 from $8,232.07

for 14 milliliters
Quantity Per unit Price
14 milliliters $588.01 $8,232.07

Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.

1200 mg/20 mL

Tecentriq intravenous solution

 from $11,756.14

for 20 milliliters
Quantity Per unit Price
20 milliliters $587.81 $11,756.14

Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.

Drugs.com Printable Discount Card

The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.

Print Free Discount Card

Note: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.

Tecentriq Coupons, Copay Cards and Rebates

Tecentriq offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.

Tecentriq Genentech Oncology Co-pay Assistance Program

Eligible commercially insured patients may pay $0 in out-of-pocket costs for the prescribed product; savings of up to $25,000 per product per calendar year.

Applies to:
Tecentriq
Number of uses:
Per prescription per calendar year

Form more information phone: 855-692-6729 or Visit website

Tecentriq Genentech Oncology Co-pay Assistance Program Rebate

Eligible commercially insured patients enrolled in the program may be entitled to a rebate for their out-of-pocket cost if they paid the provider directly for treatment.

Applies to:
Tecentriq
Number of uses:
One rebate per prescription fill

Form more information phone: 855-692-6729 or Visit website

Tecentriq Hybreza Genentech Oncology Co-pay Assistance Program

Eligible commercially insured patients may pay as little as $0 per treatment.

Applies to:
Tecentriq Hybreza
Number of uses:
Per length of program

Form more information phone: 855-692-6729 or Visit website

Patient Assistance & Copay Programs for Tecentriq

Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.

Provider: Patient Access Network Foundation (PAN)

Eligibility requirements:
  1. *See Additional Information section below
  2. Between 400-500% of FPL
  3. FDA Approved Diagnosis - See Program Website for Details
  4. Must reside and receive treatment in US
  5. *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
Applicable drugs:
  • Tecentriq (atezolizumab) Injection; IV
  • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Injection for Subcutaneous use

More information please phone: 866-316-7263 Visit Website

Provider: Genentech Oncology Access Solutions

Eligibility requirements:
  1. Determined case by case
  2. Based on FPL
  3. Varies
  4. Must be treated by US licensed healthcare provider
  5. Call for most recent medications as the list is subject to change. Eligibility determined on a case-by-case basis. Contact program for details.
Applicable drugs:
  • Tecentriq (atezolizumab) Injection; IV
  • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Injection for Subcutaneous use

More information please phone: 888-249-4918   or 866-422-2377   Visit Website

Provider: Genentech Patient Foundation

Eligibility requirements:
  1. Uninsured or Underinsured with no prescription coverage for needed medication
  2. Based on FPL
  3. Medically appropriate condition/diagnosis
  4. Must be treated by US licensed healthcare provider
  5. The Genentech Access to Care Foundation is now the Genentech Patient Foundation. Eligibility determined on a case-by-case basis. Call for most recent medications as the list is subject to change. This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details.
Applicable drugs:
  • Tecentriq (atezolizumab) Injection; IV
  • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Injection for Subcutaneous use

More information please phone: 888-941-3331   or 866-422-2377   Visit Website

Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.